游离皮质醇与游离21-脱氧皮质醇在先天性肾上腺增生症临床评估中的应用
本研究开发并验证了液相色谱串联质谱法测定游离皮质醇和游离21-脱氧皮质醇,在未经治疗的经典型先天性肾上腺增生症(CAH)患者、非经典型CAH患者、其他肾上腺功能不全患者及对照者中于Synacthen刺激前后进行测定。结果显示经典型CAH患者基础总皮质醇低于非经典型CAH和对照,但游离皮质醇相似;21-羟化酶缺陷患者基础游离21-脱氧皮质醇高,刺激后升高而游离皮质醇不变。结论认为经典型CAH患者皮质醇可用性与对照相当,游离21-脱氧皮质醇可能解释部分患者症状少,评估CAH患者肾上腺功能不全时应考虑游离皮质醇和21-脱氧皮质醇水平。
要点
- 经典型CAH患者基础总皮质醇中位数109 nmol/L,低于非经典型CAH的249 nmol/L(P=.010)和对照的202 nmol/L(P=.016),但游离皮质醇浓度相似。
- 21-羟化酶缺陷患者基础游离21-脱氧皮质醇中位数5.32 nmol/L,肾上腺功能不全患者和对照均检测不到(<0.19 nmol/L)。
- Synacthen刺激后21-羟化酶缺陷患者游离21-脱氧皮质醇升高,而游离皮质醇不变。
核心结论
- 经典型CAH患者游离皮质醇浓度与对照和非经典型CAH患者相似,提示皮质醇可用性相当。
- 21-羟化酶缺陷患者产生高浓度21-脱氧皮质醇,可能解释部分经典型21-羟化酶缺陷患者症状少。
- 评估CAH患者肾上腺功能不全时应考虑游离皮质醇和21-脱氧皮质醇水平。
研究设计与样本
- 开发并验证了测定游离皮质醇和游离21-脱氧皮质醇的液相色谱串联质谱法。
- 在未经治疗的经典型CAH患者(n=29)、非经典型CAH患者(n=5)、其他肾上腺功能不全患者(n=3)和对照者(n=11)中,于Synacthen刺激前和刺激后60分钟测定总及游离血清皮质醇和21-脱氧皮质醇浓度。
主要发现
- 未经治疗的经典型CAH患者基础总皮质醇中位数109 nmol/L,低于未经治疗的非经典型CAH患者的249 nmol/L(P=.010)和对照者的202 nmol/L(P=.016),但游离皮质醇浓度相似。
- 21-羟化酶缺陷患者基础游离21-脱氧皮质醇中位数5.32 nmol/L,肾上腺功能不全患者和对照者检测不到(<0.19 nmol/L)。
- Synacthen给药后,21-羟化酶缺陷患者游离21-脱氧皮质醇浓度升高,而游离皮质醇浓度不变。
临床怎么用
- 原文结论认为评估CAH患者肾上腺功能不全时应考虑游离皮质醇和21-脱氧皮质醇水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Some patients with classic congenital adrenal hyperplasia (CAH) survive without glucocorticoid treatment. Increased precursor concentrations in these patients might lead to higher free (biological active) cortisol concentrations by influencing cortisol-protein binding. In 21-hydroxylase deficiency (21OHD), the most common CAH form, accumulated 21-deoxycortisol (21DF) may further increase glucocorticoid activity. Both mechanisms could explain the low occurrence of symptoms in some patients with untreated classic CAH. OBJECTIVE: Develop and validate a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for free cortisol and free 21DF to quantify these steroids in patients with untreated classic CAH before and after Synacthen administration, and compare these concentrations to concentrations measured in patients with nonclassic CAH (NCCAH), other forms of adrenal insufficiency (AI), and controls. METHODS: An LC-MS/MS method to measure free cortisol and free 21DF was developed and validated. Total and free serum concentrations of both cortisol and 21DF were measured in patients with untreated classic CAH (n = 29), NCCAH (n = 5), AI (n = 3), and controls (n = 11) before and 60 minutes after stimulation with Synacthen. RESULTS: Unstimulated total cortisol concentrations of patients with untreated classic CAH (median 109 nmol/L) were lower than in patients with untreated NCCAH (249 nmol/L, P = .010) and controls (202 nmol/L, P = .016), but free cortisol concentrations were similar. Basal free 21DF concentrations were high in patients with 21OHD (median 5.32 nmol/L) and undetectable in patients with AI and controls (<0.19 nmol/L). After Synacthen administration, free 21DF concentrations increased in patients with 21OHD, while free cortisol concentrations did not change. CONCLUSION: Free cortisol concentrations in patients with classic CAH were similar to those in controls and patients with NCCAH, indicating comparable cortisol availability. Additionally, patients with 21OHD produce high concentrations of 21DF, possibly explaining the low occurrence of symptoms in some patients with classic 21OHD. Free cortisol and 21DF levels should be considered in evaluating adrenal insufficiency in patients with CAH.
引用
- Adriaansen BPH, Utari A, Olthaar AJ, et al. Free Cortisol and Free 21-Deoxycortisol in the Clinical Evaluation of Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2025. PMID: 39183148. doi:10.1210/clinem/dgae591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。